Weekly Pharma & Life Science News Round-Up: 1st – 5th August
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 1st-5th August.
Calibre Scientific is pleased to announce the acquisition of Agar Scientific, a global manufacturer and distributor of microscopy consumables and equipment with headquarters in Stansted, United Kingdom.
Finalization of Vifor Pharma acquisition
CSL Limited is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma announced on 14 December 2021.
Carterra, Inc. and La Jolla Institute for Immunology (LJI) announce that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.
SpectrumX announces its partnership with a leading UK-based specials contract manufacturing group with global reach to advance the production of its ground-breaking anti-pathogenic medicine for use in its planned Phase I clinical trials.
Assure Infusions to build pharmaceutical manufacturing facility in Central Florida
Assure Infusions is building a manufacturing plant in Bartow, Florida. The 60,000-square-foot-facility – scheduled to open in 2023 – will be fully automated with advanced robotics to make IV fluids that are in high demand in the U.S. healthcare system.
Heriot-Watt University and InnoScot Health pool expertise to accelerate medtech innovation
A partnership which aims to fast-track innovation in medical and healthcare technologies and better understand clinical and nursing needs in Scotland has been announced by Heriot-Watt University and InnoScot Health.
Bio-Rad acquires Curiosity Diagnostics
Bio-Rad Laboratories announced that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets.
Gilead Sciences to acquire MiroBio
Gilead Sciences, Inc. and MiroBio announce that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
Bayer tops the Equality, Diversity and Inclusion leader board in multibillion pharma industry
A new report by stakeholder intelligence firm alva has revealed the leaders in the multibillion-pound pharma industry when it comes to Equality, Diversity and Inclusion (EDI). Post-pandemic, EDI is becoming a strategic imperative for pharma organisations.
invoX Pharma extends tender offer to acquire F-star Therapeutics, Inc
invoX and F-star Therapeutics, Inc. announce that invoX has extended the expiration of its previously announced tender offer for all of the issued and outstanding shares of F-star common stock for a price of $7.12 per share.
BioMed X announces the start of its new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany.
Ipsen and Marengo Therapeutics, Inc. announce a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic.
The BWB Awards at Biotech Week Boston 2022: celebrating excellence in life sciences
The BWB Awards at Biotech Week Boston return in-person to recognize the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have brought together the faces and names that make Boston the beating heart of the biotech world.
Sosei Group Corporation and AbbVie announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulates novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
AbCellera and Atlas Venture announce a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company.
